Predicting cancer return after tumor ablation
Part of Brain & nervous system, Cancer, Digestive system, Mental health clinical trials.
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a first-time diagnosis of liver cancer (hepatocellular carcinoma).
- You can have one tumor smaller than 5 cm, or 2 to 3 tumors all smaller than 3 cm.
- Your first treatment for this cancer must be radiofrequency ablation (RFA).
- You must agree to answer a questionnaire and be followed for at least 6 months after ablation.
- You cannot have had the cancer spread outside the liver or into blood vessels before treatment.
- You cannot have severe liver problems, other cancers, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new criteria for evaluating how well thermal ablation (using heat to destroy cancer nodules) worked in people with hepatocellular carcinoma (HCC, a type of liver cancer). It aims to improve follow-up imaging with contrast-enhanced ultrasound (CEUS) or CT/MRI to see if the treatment was successful.
This study compares two ways to remove a recurrence of liver cancer: laparoscopic surgery (small belly cuts) versus RFA (a heat treatment through a needle). It aims to see which option works better for people with a limited-size, limited-location recurrence and good liver function.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.